CAS 942947-93-5|CCT129202

Introduction:Basic information about CAS 942947-93-5|CCT129202, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Common NameCCT129202
CAS Number942947-93-5Molecular Weight497.016
Density1.4±0.1 g/cm3Boiling Point/
Molecular FormulaC23H25ClN8OSMelting Point/
MSDS/Flash Point/

Names

Name2-[4-[6-chloro-2-[4-(dimethylamino)phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]piperazin-1-yl]-N-(1,3-thiazol-2-yl)acetamide
SynonymMore Synonyms

CCT129202 BiologicalActivity

DescriptionCCT 137690 is an aurora kinase inhibitor with IC50s of 42, 198, and 227 nM for aurora A, B and C, respectively.
Related CatalogResearch Areas >>Cancer
Target

Aurora A:142 nM (IC50)

Aurora B:198 nM (IC50)

Aurora C:227 nM (IC50)

In VitroCCT129202 causes the accumulation of human tumor cells with z4N DNA content, leading to apoptosis. CCT129202 is found to induce apoptosis with GI50 values that ranges between 0.08 and 1.7 μM. CCT120202-treated human tumor cells shows a delay in mitosis, abrogation of nocodazole-induced mitotic arrest, and spindle defects. CCT129202 Causes p21Up-regulation, Rb Hypophosphorylation, and H2F-DependentTK1Down-regulation[1].
In VivoGrowth of HCT116 xenografts in nude mice is inhibited after i.p. administration of CCT129202. p21, the cyclin-dependent kinase inhibitor, is induced by CCT129202. Up-regulation of p21 by CCT129202 in HCT116 cells led to Rb hypophosphorylation and E2F inhibition, contributing to a decrease in thymidine kinase 1 transcription[1].
Cell AssayThe effects of CCT129202 on cell proliferation are analyzed with the MTT assay. Cells are plated in 96-well plates at 2,500 per well and are treated with a range of 0 to 50 μM of CCT129202 for 72 h. The absorbance is measured at 570 nm[1].
Animal AdminMice: For efficacy studies, human HCT116 colon carcinoma xenografts are established in female mice. CCT129202 is dissolved in DMSO and injected i.p in vehicle, which comprises 10% DMSO, 5% Tween 20, and 85% sterile saline at 0.1 mL/10 g body weight. Dosing with CCT129202 commenced when tumors are well established (f5 mm mean diameter); control animals receive an equivalent volume of vehicle. Mouse body weights and condition are monitored throughout the study. Tumors are measured thrice weekly[1].
References

[1]. Chan F, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3147-57.

Chemical & Physical Properties

Density1.4±0.1 g/cm3
Molecular FormulaC23H25ClN8OS
Molecular Weight497.016
Exact Mass496.156067
PSA125.01000
LogP4.94
Index of Refraction1.719
InChIKeyQYKHWEFPFAGNEV-UHFFFAOYSA-N
SMILESCN(C)c1ccc(-c2nc3ncc(Cl)c(N4CCN(CC(=O)Nc5nccs5)CC4)c3[nH]2)cc1
Storage condition-20℃

Synonyms

1-Piperazineacetamide, 4-[6-chloro-2-[4-(dimethylamino)phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]-N-2-thiazolyl-
2-(4-{6-chloro-2-[4-(dimethylamino)phenyl]-3H-imidazo[4,5-b]pyridin-7-yl}piperazin-1-yl)-N-(1,3-thiazol-2-yl)acetamide
S1519_Selleck
cc-472
1-Piperazineacetamide,4-(6-chloro-2-(4-(dimethylamino)phenyl)-3H-imidazo(4,5-b)pyridin-7-yl)-N-2-thiazolyl
2-(4-{6-Chloro-2-[4-(dimethylamino)phenyl]-1H-imidazo[4,5-b]pyridin-7-yl}-1-piperazinyl)-N-(1,3-thiazol-2-yl)acetamide
CCT129202
CAS 1585-68-8|Catalpalactone
CAS 1095382-05-0|CCT 137690
Recommended......
TOP